# Personalized & regenerative medicine Gene and cell therapy platforms for rare monogenic and oncological diseases: AAV vectors, lentiviral HSC editing, ex vivo CRISPR (Casgevy) and in vivo CRISPR (LNP delivery) now deliver durable one-time treatments approved by FDA and EMA. Source: https://en.bioecon.ru/technology/personalized-regenerative-medicine/ Updated: 2026-09-02 ## Overview and value chain Markers: [EC: ATMP Regulation (EC No 1394/2007) | OECD: Bio-Pharmaceuticals | Regulator: FDA (USA), EMA (EU), NMPA (China)] Personalized and regenerative medicine delivers durable, often one-time treatments by correcting or replacing disease-causing genetic defects at the cellular level. Four approved product classes now coexist: AAV gene replacement (Zolgensma $2.125M for SMA, Elevidys $3.2M for DMD), lentiviral HSC gene addition (Libmeldy, Strimvelis), ex vivo CRISPR editing of autologous stem cells (Casgevy $2.2M for sickle cell / beta-thal), and in vivo CRISPR via lipid nanoparticle delivery (Intellia lonvo-z Phase 3 positive in HAE, rolling BLA 2026). The global ATMPs market exceeded $5B in 2025 and is projected to reach $25B by 2030 at >30% CAGR. Manufacturing remains the dominant bottleneck: AAV vector production requires specialised cGMP bioreactor suites; ex vivo CRISPR requires patient-specific manufacturing windows of 4–8 weeks. The key platforms of personalized & regenerative medicine are: 1. **AAV Gene Replacement (AAV Gene Therapy):** single-stranded recombinant AAV vectors (serotypes rh74, AAV9) deliver a functional gene copy; one administration produces durable expression >3 years in SMA and DMD clinical data. 2. **Lentiviral HSC Gene Addition (Lentiviral Gene Therapy):** ex vivo transduction of autologous haematopoietic stem cells; approved for ADA-SCID, MLD (OTL-200/Libmeldy) and X-ALD. 3. **Ex vivo CRISPR editing (CRISPR/Cas9 HSC):** Cas9 knocks out BCL11A in autologous HSCs to reactivate foetal haemoglobin — basis of Casgevy (exa-cel), first CRISPR medicine approved by FDA (Dec 2023) and EMA. 4. **In vivo CRISPR via LNP (LNP-CRISPR):** ionisable LNPs deliver Cas9 mRNA + sgRNA to hepatocytes; Intellia lonvo-z achieves >95% TTR knockdown in HAE (Phase 3 HAELO, 2026); clinical proof of concept for redosing demonstrated. ### Sectoral value chain ``` [patient biopsy / HSC harvest] ──> [vector mfg / cell engineering] │ (QC release, cGMP batch) │ ▼ [patient] <─── [infusion / in vivo dosing] <─── [hospital treatment centre] ``` ### Value chain levels | Level | Description | Key inputs/outputs | |:---|:---|:---| | **Cell/vector sourcing** | Patient HSC apheresis or AAV plasmid production | **In:** patient or donor cells / plasmid DNA. **Out:** starting material. | | **Vector / gene construct manufacturing** | Suspension HEK293 triple-transfection (AAV) or lentiviral packaging; GMP bioreactor 200–2,000 L | **In:** plasmid, cells, bioreactor capacity. **Out:** crude viral vector harvest. | | **Purification & formulation** | AEX / CsCl ultracentrifugation for AAV; TFF + filtration for LV; fill into vials | **In:** crude harvest. **Out:** GMP drug substance. | | **Patient cell engineering (ex vivo)** | HSC isolation, transduction / electroporation, expansion 14–21 days | **In:** patient HSCs, vector / RNP. **Out:** engineered cell product. | | **QC release** | Potency, sterility, identity, vector genome titre, RCV testing; 4–8 weeks | **In:** drug product. **Out:** released lot. | | **Administration & follow-up** | Conditioning chemotherapy + infusion; ≥2 years safety monitoring | **In:** patient, released product. **Out:** treated patient + long-term outcome. | Cross-cutting technologies of the sector: - **Lipid nanoparticles (LNP delivery):** ionisable LNP enables in vivo hepatic delivery of mRNA/RNP; critical for in vivo CRISPR and personalised mRNA therapeutics. - **Base editing / prime editing:** precise single-nucleotide changes without DSB — next wave after Cas9; Beam Therapeutics and Prime Medicine advancing clinically. - **Cell process automation:** closed automated systems (CliniMACS Prodigy, Lonza Cocoon) reduce manual steps and enable decentralised manufacturing. --- ## US The US leads globally with >15 approved ATMPs and the largest clinical-stage pipeline; FDA issued Breakthrough and RMAT designations for >40 gene therapy programs in 2025 alone. ### AAV approvals, CRISPR first approvals, RMAT pipeline - **Sarepta / Elevidys:** FDA expanded Elevidys (delandistrogene moxeparvovec-rokl, AAV rh74) to all ambulatory and non-ambulatory DMD patients ≥4 years; 3-year EMBARK data shows sustained slowing of disease progression. - **CRISPR Therapeutics + Vertex / Casgevy:** first CRISPR medicine in history, FDA approved Dec 2023 for SCD and Jan 2024 for TDT; ~1,000 US patients ≥12 yr eligible; paediatric sNDA under review 2026. - **Intellia / lonvo-z:** Phase 3 HAELO data published New England Journal of Medicine (June 2026), rolling BLA submitted; US launch anticipated H1 2027 — first in vivo CRISPR therapy approaching approval. --- ## CN China is building a domestic gene therapy industry under NMPA's accelerated ATMP pathway, with EdiGene and domestic CDMOs advancing CRISPR and viral vector programs. ### NMPA ATMP pathway, domestic CRISPR, viral vector CDMOs - **EdiGene (博雅辑因):** leading Chinese CRISPR gene editing company; ET-01 (base editing for beta-thalassaemia) in IND-enabling; CRISPR HSC programs under NMPA Fast Track. - **Domestic vector CDMOs:** WuXi Advanced Therapies, SinoGene providing AAV and lentiviral vector manufacturing for Chinese and global sponsors. - **NMPA ATMP accelerated pathway:** special approval category for innovative gene and cell therapies; priority review timeline 6–9 months for breakthrough designation. --- ## EU Europe leads in lentiviral HSC gene therapy approvals (Libmeldy, Strimvelis, Skysona) and in allogeneic CAR-T development; ATMP regulation under EMA's CAT committee is the gold standard globally. ### EMA ATMP approvals, allogeneic CAR-T, Innovation Passport - **Orchard Therapeutics (Kyowa Kirin):** OTL-200/Libmeldy EMA-approved for MLD; OTL-203 (MPS-I Hurler) completed registrational enrolment 1 year ahead of schedule; OTL-201 (MPS-IIIA) awarded Innovation Passport (UK ILAP) April 2026. - **Novartis / Itvisma:** positive CHMP opinion April 2026 for intrathecal onasemnogene abeparvovec for SMA patients ≥2 years — extends Zolgensma reach to older/heavier patients. - **Cellectis / lasme-cel:** FDA RMAT designation June 2026 for allogeneic TALEN-edited UCART22 in r/r B-ALL; Phase 1 100% response rate; pivotal trial initiated — only allogeneic CAR-T in a pivotal trial globally. --- ## Leading companies and research institutes | Company / Institute | Country | Key products / platforms | Tech features | Status 2026 | |:---|:---|:---|:---|:---| | **Intellia Therapeutics** | 🇺🇸 USA | *lonvo-z / nex-z* | in vivo CRISPR LNP | BLA rolling | | **CRISPR Therapeutics** | 🇨🇭 Switzerland | *Casgevy* | ex vivo CRISPR/Cas9 | Commercial | | **Sarepta Therapeutics** | 🇺🇸 USA | *Elevidys* | AAV rh74 micro-dystrophin | Commercial | | **Orchard Therapeutics** | 🇬🇧 UK | *OTL-200/201/203* | lentiviral HSC editing | Commercial | | **Cellectis** | 🇫🇷 France | *lasme-cel (UCART22)* | TALEN allogeneic CAR-T | Pivotal | | **Novartis** | 🇨🇭 Switzerland | *Zolgensma / Itvisma* | AAV9 gene replacement | Commercial | --- ## Tech stack and innovations The stack spans viral vector manufacturing, precision gene editing, and LNP delivery — each addressing a distinct disease class and manufacturing model. 1. **AAV gene replacement (AAV9 / rh74):** - single-stranded recombinant AAV; serotype determines tissue tropism (AAV9 — CNS/muscle, rh74 — muscle); produced in HEK293 triple-transfection or baculovirus/Sf9. - Zolgensma maintains motor-function improvements >5 years post single IV dose in SMA Type 1. 2. **Ex vivo CRISPR/Cas9 (HSC editing):** - patient HSCs mobilised, collected, edited (electroporation of Cas9 RNP), expanded, reinfused after myeloablative conditioning. - Casgevy: BCL11A enhancer knockout reactivates HbF >30%; >95% of SCD/TDT patients free from severe VOCs or transfusions at 24 months. 3. **In vivo LNP-CRISPR (hepatic delivery):** - ionisable LNPs (~80 nm) deliver Cas9 mRNA + sgRNA after IV infusion; liver tropism enables knockdown of secreted disease proteins. - lonvo-z: >95% median TTR reduction in ATTR amyloidosis; redosing proof of concept demonstrated; HAELO Phase 3 showed >90% reduction in HAE attacks vs placebo. --- ## Value chains and production pipelines ### Gene therapy manufacturing pipeline (ATMP / cGMP ISO 13485) ``` ┌───────────────────────────┐ ┌───────────────────────────┐ │ 1. Plasmid / vector prep │ ───> │ 2. Upstream manufacturing │ └───────────────────────────┘ └───────────────────────────┘ │ ▼ ┌───────────────────────────┐ ┌───────────────────────────┐ │ 4. Cell engineering (ex v)│ <─── │ 3. Downstream purification│ └───────────────────────────┘ └───────────────────────────┘ │ ▼ ┌───────────────────────────┐ ┌───────────────────────────┐ │ 5. QC release & fill-fin. │ ───> │ 6. Clinical administration│ └───────────────────────────┘ └───────────────────────────┘ ``` #### Stage 1: Plasmid and vector preparation GMP plasmid DNA production (transfer vector, packaging plasmid, envelope plasmid) in E. coli fermentation at 10–200 L scale; or AAV ITR-flanked transfer plasmid; endotoxin <0.25 EU/mL specification. #### Stage 2: Upstream manufacturing HEK293 triple-transfection in 50–200 L stirred-tank bioreactor (AAV) or lentiviral packaging; Baculovirus/Sf9 platform for large-scale AAV; cell density 2–5 × 10⁶ cells/mL, harvest at 72–96 h post-transfection. #### Stage 3: Downstream purification Iodixanol / CsCl ultracentrifugation or AEX + SEC chromatography for AAV; TFF + AEX for lentiviral; target: >1 × 10¹³ vg/mL, full/empty capsid ratio >90%, residual DNA <10 ng/dose. #### Stage 4: Cell engineering (ex vivo route) Patient HSC mobilisation (G-CSF + plerixafor), apheresis, CD34+ selection, electroporation of Cas9 RNP or lentiviral transduction; expansion 14–21 days; cell viability >80%, transduction efficiency >70%. #### Stage 5: QC release and fill-finish Potency assay (genome titre by ddPCR, transduction efficiency, HbF induction for Casgevy); sterility; identity (VCN, editing efficiency); replication-competent virus (RCV) testing; batch release 4–8 weeks; fill into cryobags or vials. #### Stage 6: Clinical administration Conditioning chemotherapy (busulfan myeloablation for HSC products); IV infusion or intrathecal injection (Itvisma); 2+ years safety follow-up per FDA/EMA requirement; patient outcome measured by disease biomarkers (VOCs, motor function scores, TTR levels).